NASDAQ · AGIO
Agios Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AGIO: Nov 05, 2026
Agios Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.34. The reported EPS for the same quarter last year was $-1.78.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.34 | $-1.08 | $-1.79 | 4 |
| Dec 2026 | $-1.34 | $-0.95 | $-1.76 | 3 |
| Mar 2027 | $-1.20 | $-0.81 | $-1.59 | 2 |
| Jun 2027 | $-1.21 | $-0.82 | $-1.60 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · The Motley Fool- RTTNews · Oct 30, 10:30 AM EDTFDA Extends Agios' Mitapivat Sickle Cell Disease Review; New PDUFA Date Set; Stock Down(RTTNews) – Agios Pharmaceuticals (AGIO) announced that the U.S. Food and Drug Administration (FDA) extended the review period for its supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease, setting a new PDUFA goal date of February 1, 2027.
- RTTNews · Oct 30, 9:32 AM EDTAgios Gets New FDA Goal Date For Mitapivat In Sickle Cell Disease(RTTNews) – Agios Pharmaceuticals (AGIO) has received a new FDA PDUFA goal date of February 1, 2027, for its mitapivat supplemental application in sickle cell disease.
- Zacks · Oct 29, 9:00 AM EDTAgios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseAgios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- RTTNews · Oct 29, 4:01 AM EDTBiotech Stocks Facing FDA Decision In November 2026(RTTNews) – The FDA's November calendar has more than a dozen PDUFA dates on the horizon, setting the stage for an eventful month in the regulatory landscape.
- Zacks · Oct 28, 4:45 PM EDTLENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue EstimatesLENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -2.06% and -15.67%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 21, 9:45 AM EDTDHR Q3 Earnings Beat on Biotechnology Strength, Sales in LineDanaher's third-quarter earnings beat estimates by 9.9%, driven by stronger Biotechnology profitability, while it raised its 2026 adjusted earnings outlook.
- Zacks · Oct 16, 8:41 AM EDTDanaher Gears Up to Post Q3 Earnings: What Lies Ahead for the Stock?DHR's Q3 results are due Oct. 21, with growth in Biotechnology, Diagnostics and Life Sciences expected to boost revenues, while rising costs and currency headwinds weigh on earnings.
- The Motley Fool · Oct 14, 6:28 AM EDT4 High-Risk Stocks Built for Big ReturnsPatience and diversification are emphasized for these speculative picks, given their downside risk and upside potential.
- Zacks · Oct 6, 9:55 AM EDTAGIO Stock Sinks 29% in Three Months: Here's What You Need to KnowAgios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.
- Zacks · Oct 2, 9:22 AM EDTAgios' Growth Story Hinges on Mitapivat's Commercial ExpansionAGIO's mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.
- Zacks · Sep 4, 11:30 AM EDTRevolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?Revolution Medicines (RVMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks · Jul 31, 12:17 PM EDTAGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over YearAgios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Agios Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.